CA3000815A1 - Anticorps anti-age et procedes d'utilisation correspondants - Google Patents
Anticorps anti-age et procedes d'utilisation correspondants Download PDFInfo
- Publication number
- CA3000815A1 CA3000815A1 CA3000815A CA3000815A CA3000815A1 CA 3000815 A1 CA3000815 A1 CA 3000815A1 CA 3000815 A CA3000815 A CA 3000815A CA 3000815 A CA3000815 A CA 3000815A CA 3000815 A1 CA3000815 A1 CA 3000815A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- age
- sequence identity
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
L'invention concerne un anticorps anti-AGE, comprenant une protéine ou un peptide qui comprend au moins une séquence d'acides aminés présentant une identité de séquence d'au moins 90 %, de préférence une identité de séquence d'au moins 95 %, plus préférablement une identité de séquence d'au moins 98 %, par rapport à des séquences d'acides aminés spécifiques. L'anticorps anti-AGE se lie à une protéine ou à un peptide qui présente une modification carboxyméthyllysine. L'anticorps anti-AGE peut être utilisé pour tuer des cellules sénescentes, pour tuer des cellules partiellement fonctionnelles ou non fonctionnelles, pour traiter la sarcopénie, pour favoriser la régénération d'organes ou de tissus, pour favoriser des processus de régénération ou surmonter les effets de vieillissement, pour traiter l'athérosclérose, pour prévenir ou retarder l'apparition de la cataracte, pour prévenir ou retarder l'apparition d'une perte de tissu adipeux, pour augmenter la durée de vie en santé, pour prévenir ou retarder l'apparition de la lordo-cyphose, pour traiter l'inflammation ou les maladies auto-immunes, pour traiter des troubles neurodégénératifs ou pour traiter le cancer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562241007P | 2015-10-13 | 2015-10-13 | |
US62/241,007 | 2015-10-13 | ||
US14/974,561 | 2015-12-18 | ||
US14/974,561 US10358502B2 (en) | 2014-12-18 | 2015-12-18 | Product and method for treating sarcopenia |
PCT/US2016/034880 WO2017065837A1 (fr) | 2015-10-13 | 2016-05-27 | Anticorps anti-age et procédés d'utilisation correspondants |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3000815A1 true CA3000815A1 (fr) | 2017-04-20 |
CA3000815C CA3000815C (fr) | 2022-11-01 |
Family
ID=58518256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3000815A Active CA3000815C (fr) | 2015-10-13 | 2016-05-27 | Anticorps anti-age et procedes d'utilisation correspondants |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3362483A1 (fr) |
JP (1) | JP2018535953A (fr) |
KR (1) | KR20180056689A (fr) |
CN (1) | CN108431044A (fr) |
AU (1) | AU2016336959A1 (fr) |
BR (1) | BR112018007422A2 (fr) |
CA (1) | CA3000815C (fr) |
IL (1) | IL258397A (fr) |
MA (1) | MA42979A (fr) |
MX (1) | MX2018004545A (fr) |
RU (1) | RU2766209C2 (fr) |
WO (1) | WO2017065837A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2294178B1 (fr) | 2008-05-23 | 2014-07-16 | Siwa Corporation | Procédés facilitant la régénération |
WO2012047629A2 (fr) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Élimination sélective de cellules modifiées par age pour le traitement de l'athérosclérose |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
IL251210B2 (en) | 2014-09-19 | 2023-12-01 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
EP4067386A1 (fr) * | 2016-02-19 | 2022-10-05 | Siwa Corporation | Procédé et composition pour traiter le cancer, tuer des cellules du cancer métastatique et prévenir des métastases cancéreuses à l'aide d'anticorps pour produits finaux de glycosylation avancée (rage) |
WO2018191718A1 (fr) * | 2017-04-13 | 2018-10-18 | Siwa Corporation | Anticorps monoclonal humanisé de produit final de glycation avancée |
CA3057829A1 (fr) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anticorps anti-age pour le traitement de troubles neurodegeneratifs |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
KR20240006702A (ko) * | 2017-05-04 | 2024-01-15 | 시와 코퍼레이션 | 진단용 최종 당화 산물 항체 |
JP6994876B2 (ja) * | 2017-09-05 | 2022-01-14 | 株式会社エッグ | 計測器 |
WO2019183282A1 (fr) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Agents sénolytiques pour le traitement de tauopathies |
EP3826670A1 (fr) * | 2018-07-23 | 2021-06-02 | Siwa Corporation | Méthodes et compositions destinées à traiter les effets chroniques de l'exposition aux rayonnements et aux substances chimiques |
JP2021534144A (ja) * | 2018-08-23 | 2021-12-09 | シワ コーポレーション | Age修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波 |
CN114957470B (zh) * | 2021-11-12 | 2023-01-17 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
WO2023177390A1 (fr) * | 2022-03-14 | 2023-09-21 | Siwa Corporation | Anticorps monoclonal humanisé de produit final de glycation avancée pour le traitement du cancer du pancréas |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
CN101121021B (zh) * | 1999-06-25 | 2011-12-07 | 杰南技术公司 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
JP4012722B2 (ja) * | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
EP1988918A4 (fr) | 2006-02-22 | 2010-04-28 | Novavax Inc | Compositions d'adjuvant et de vaccin |
EP2294178B1 (fr) | 2008-05-23 | 2014-07-16 | Siwa Corporation | Procédés facilitant la régénération |
-
2016
- 2016-05-27 KR KR1020187010762A patent/KR20180056689A/ko not_active Application Discontinuation
- 2016-05-27 JP JP2018519727A patent/JP2018535953A/ja active Pending
- 2016-05-27 MA MA042979A patent/MA42979A/fr unknown
- 2016-05-27 EP EP16731696.7A patent/EP3362483A1/fr not_active Withdrawn
- 2016-05-27 RU RU2018110885A patent/RU2766209C2/ru active
- 2016-05-27 BR BR112018007422A patent/BR112018007422A2/pt not_active Application Discontinuation
- 2016-05-27 CA CA3000815A patent/CA3000815C/fr active Active
- 2016-05-27 WO PCT/US2016/034880 patent/WO2017065837A1/fr active Application Filing
- 2016-05-27 CN CN201680059997.5A patent/CN108431044A/zh active Pending
- 2016-05-27 MX MX2018004545A patent/MX2018004545A/es unknown
- 2016-05-27 AU AU2016336959A patent/AU2016336959A1/en not_active Abandoned
-
2018
- 2018-03-27 IL IL258397A patent/IL258397A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Also Published As
Publication number | Publication date |
---|---|
MX2018004545A (es) | 2018-08-01 |
EP3362483A1 (fr) | 2018-08-22 |
BR112018007422A2 (pt) | 2018-10-30 |
IL258397A (en) | 2018-05-31 |
CN108431044A (zh) | 2018-08-21 |
RU2766209C2 (ru) | 2022-02-09 |
RU2018110885A3 (fr) | 2020-01-30 |
RU2018110885A (ru) | 2019-11-19 |
JP2018535953A (ja) | 2018-12-06 |
AU2016336959A1 (en) | 2018-04-12 |
KR20180056689A (ko) | 2018-05-29 |
MA42979A (fr) | 2021-05-26 |
CA3000815C (fr) | 2022-11-01 |
WO2017065837A1 (fr) | 2017-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3000815C (fr) | Anticorps anti-age et procedes d'utilisation correspondants | |
US11873345B2 (en) | Product and method for treating sarcopenia | |
US10889634B2 (en) | Anti-age antibodies and methods of use thereof | |
US11958900B2 (en) | Anti-age antibodies for treating neurodegenerative disorders | |
CA3021150C (fr) | Procede et composition pour traiter le cancer, detruire les cellules cancereuses metastatiques et prevenir la metastase cancereuse en utilisant des anticorps contre les produits t erminaux de glycation avancee (age) | |
US11542324B2 (en) | Humanized monoclonal advanced glycation end-product antibody | |
US10858449B1 (en) | Methods and compositions for treating osteoarthritis | |
WO2023177390A1 (fr) | Anticorps monoclonal humanisé de produit final de glycation avancée pour le traitement du cancer du pancréas | |
AU2018251183B2 (en) | Humanized monoclonal advanced glycation end-product antibody | |
GRUBER | Patent 3000815 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20210427 |
|
EEER | Examination request |
Effective date: 20210427 |
|
EEER | Examination request |
Effective date: 20210427 |
|
EEER | Examination request |
Effective date: 20210427 |